While patients with high CD8+ T cell density in the tumor infiltrate have a more favorable prognosis across many other neoplastic diseases (6), little is still known about the presence and clinical impact of CD8+ T cells in LCH-lesions (7–9). The gene discussed is CD8A; the disease is Langerhans cell histiocytosis.